A mutant of polyomavirus, F441, selected to grow in undifferentiated mouse F9 embryonal carcinoma cells, carries a single-base change in the enhancer region at nucleotide (nt) 5233 of the viral genome. Enhancers of most of the F9 mutants have a duplicated segment of viral DNA encompassing nt 5233. The minimum duplicated segment of all the known F9 mutants is from nt 5218 to nt 5239. We prepared oligonucleotides spanning the sequence from nt 5218 through nt 5239 of the genome of the wild type and F441 and examined the biological activities of the oligonucleotides by a transient assay of chloramphenicol acetyltransferase (CAT) gene expression in F9 cells. The oligonucleotide harboring the F441 mutation was shown to increase cat gene expression in F9 cells when linked at an upstream position in both orientations. When dimerized at an upstream position, the F441 oligonucleotide showed even higher cat gene expression enhancing activity. In contrast, no such effects were observed with the oligonucleotide of the wild-type sequence. In addition, the F441 oligonucleotide, but not the wild-type sequence, could inhibit the activity of whole enhancer fragment of F441 when cotransfected into F9 cells in excess amounts. On the basis of the results obtained, we suggest that the segment of F441 enhancer encompassing the point mutation contains a target for a cellular factor(s) which acts in a positive manner to increase the transcription of a gene in undifferentiated mouse F9 cells.
Wild-type polyomavirus does not grow in mouse cell lines representative of early stages of mouse development (2, 38) . Examples include the embryonal carcinoma cell lines F9 and PCC4 (18) and trophoblast cell lines such as Tr/C57BL/6 (39) . When such cells are induced to differentiate, they become permissive to the virus growth. Mutants of polyomavirus capable of growing in these undifferentiated cells can be isolated from cells chronically infected with wild-type virus. It has been shown that the mutations are localized to the enhancer region of the viral genome (13, 20, 21, 34, 39) . In more recent reports, the enhancer region was shown to undergo changes in a differentiation-dependent manner when the virus was adapted to grow in Friend leukemia cells before and after differentiation (8, 9) and in neuroblastoma cells at various states of differentiation (27) . These observations suggest that analysis of mutated enhancers may help disclose the mechanisms by which expression of cellular genes is regulated as cells differentiate (1, 17, 24, 25) .
Alterations observed in the enhancers of embryonal carcinoma and trophoblast mutants include point mutation, deletions, duplications, sequence rearrangements, or combinations of some of these changes (summarized in references 1 and 40) . The meaning of these genetic changes was not clear until recently. As the analysis of the enhancer region of polyomavirus reveals that there are multiple redundant functional elements (17, 29, 43) and that some sequences are homologous to the enhancer cores of other viral or cellular genes, it is now possible to address specific questions concerning the nature of the changes seen in the enhancers of embryonal carcinoma and trophoblast mutants (reviewed in reference 1). In the case of F9 mutants isolated to grow in F9 cells, the simplest change found in the enhancer region is an A-to-G transition at nucleotide (nt) 5233 seen in F441 (13) or F9-1 (21) (Fig. 1) . Many other F9 mutants, including F101 and Fill (13; Fig. 1 ) and hrN2 and hrN5 (34) , have dupli-* Corresponding author.
cation of the region spanning this nt 5233 in addition to the A-to-G point mutation. A minimum border of the segment of viral DNA present in the duplicated region in all the F9 mutants reported so far is from nt 5218 to nt 5239 (Fig. 1) .
It has been suggested that a cellular factor(s) present in F9 cells recognizes the enhancer of Moloney murine sarcoma virus and inhibits its function (15) . Likewise, the enhancer of wild-type polyomavirus may be negatively regulated in F9 cells. Negative regulation of the polyomavirus enhancer by the adenovirus Ela gene, a transforming gene of the virus (5) , has also been shown to occur. Interestingly, a mutation from A to G at nt 5233 not only allows polyomavirus enhancer to function in F9 cells but also renders it insensitive to the negative effect induced by the adenovirus Ela protein (16) . These results suggest that the adenovirus Ela gene induces, in differentiated cells, a negative regulatory factor(s) which is similar to the one normally expressed in F9 cells and that an alteration of the nucleotide at position 5233 can abrogate the negative effect. Possibly this site is a binding site for a negative regulator present in F9 cells, and the point mutation from A to G results in the elimination of this binding site. Alternatively, the alteration could create a binding site for a positive-acting factor which is able to overcome the repression normally occurring in F9 cells.
To address this question, we synthesized the oligonucleotides representing a segment of polyomavirus enhancer from nt 5218 to nt 5239, spanning the nt 5233 of either A or G (Fig. 1 (41) . The nucleotide at 5233 is converted from A to G in F441 (13) and F9-1 (20 Vectors. pAj0CAT2 (23) was used as a vector for insertion of polyomavirus enhancer fragments and oligonucleotides. pSVpNEO was a derivative vector constructed in this laboratory from pA10CAT2 and pSV2NEO (36) (13, 20) . The sequence CCACCCA underlined is homologous to the core of bovine papillomavirus enhancer (26 Table 1) .
The oligonucleotides representing polyomavirus enhancer sequence from nt 5218 to nt 5239 with either A or G at nt 5233 were synthesized with BamHI sites at both ends (Fig.  2B ). This segment of DNA was chosen because it is frequently duplicated in F9 mutants, suggesting that the duplicated segment may represent a functional unit. In the original polyomavirus enhancer region, one copy each of the heptanucleotide sequence which constitutes the core sequence of the bovine papillomavirus enhancer (26) is present at both sides near nt 5233. The oligonucleotides contain only one copy of the motif at the late side of nt 5233.
We examined whether the oligonucleotide could compete with pF441EN CAT and thus affect the level of induced CAT activity. It has been suggested that an enhancer element must be linked in cis to a promoter element to achieve an efficient competition in vivo when cotransfected with a test gene controlled by that enhancer (6, 33, 45) . Thus, we prepared competitors by inserting the oligonucleotide or the enhancer fragment at an upstream position of pSVpNEO (Fig. 3C ). Since the backbone vector, pSVpNEO, was constructed to posess the same SV40 early promoter element as pA1OCAT2, the resulting competitor genes are no different from the test gene in terms of the structural feature of the enhancer-promoter complex (compare Fig. 2C (Fig. 3B) . pW. NEO containing the wild-type oligonucleotide inhibited the CAT activity only slightly. In these experiments we assumed the CAT activity obtained by cotransfecting pF441EN CAT with pSVpNEO to be 100%. The F441 oligonucleotide, but not the wild-type oligonucleotide, when present in excess amount, could compete efficiently with the function of the full-length F441 enhancer (Fig. 3B ).
As controls, we also performed the competition experiment using the whole enhancer fragment as a competitor at the test gene, with a competitor ratio of 1:12. Competition with the wild-type enhancer reduced CAT activity to 44%, whereas competition with the F441 enhancer reduced CAT activity to 15% (Fig. 3A) .
The results of in vivo competition experiments suggest that the F441 oligonucleotide contains a target sequence for a cellular factor and that the factor seems to be a positively functioning one, since removal of the factor in the competition assay resulted in the decrease of CAT activity.
F441, but not wild-type oligonucleotide, can enhance gene expression when linked in cis. Since the competition experiments described above suggested the involvement of a positive regulatory factor in the F441 enhancer, we tested directly whether the oligonucleotide itself has the ability to enhance gene expression. The wild-type or F441 oligonucleotide was inserted at an upstream position (BglII site) or downstream position (BamHI site) in the vector pA1oCAT2 in a sense or an antisense orientation. Each construct was transfected into F9 cells, and CAT activity was measured. The constructs containing the F441 oligonucleotide at an upstream position, in either orientation (pF441S CAT and pF441A. CAT), showed roughly three times higher CAT activities than the constructs containing the wild-type oligonucleotide (pWS CAT and pWA. CAT) or a backbone plasmid (pA1OCAT2) (Fig. 4) . The results indicate that the oligonucleotide containing the F441 mutation acts as though it has a mini-enhancer-like activity in F9 cells. The oligonucleotide with the F441 mutation placed downstream from the cat gene (pCAT-F441S) did not induce significant levels of CAT activity. Reproducibility of the results was vigorously checked, particularly in these experiments, by using two different plasmid DNA preparations in several independent transfection experiments. It must be noted here that the CAT activities we could detect with the pF441S CAT or pF441A CAT constructs were relatively low: from less than 5% (Fig. 4) to about 10% (Table 1) , depending on the experiments, of the activity induced by the pF441EN CAT plasmid. Our findings that the oligonucleotides could activate the cat gene only weakly even with the F441 mutant sequence may seem to be inconsistent with the evidence that they interfered with the cat gene expression to a much greater extent in a competition assay (Fig. 3) . It is conceivable, however, that the oligonucleotides have sequences necessary for a cellular factor to bind but that the binding of the factor to the sequences is not necessarily sufficient to fully activate the linked gene. It is also worth mentioning that the very short segment of the sequence, even though it represents the most important region within the enhancer, is known to function poorly by itself as an enhancer and that it works much better in conjunction with the adjacent sequences (17) .
We have also evaluated the consequences of duplication of the oligonucleotide with respect to its ability to for 120 min. Acetylated and nonacetylated forms were separated by thin-layer chromatography as described in Materials and Methods. (B) Competition by the oligonucleotides. A 2-,ug sample of DNA from the pF441EN CAT construct was cotransfected into F9 cells with 25 ,ug of DNA from pSVpNEO, pW. NEO harboring the wild-type oligonucleotide, or pF441 NEO harboring the F441 oligonucleotide. CAT activity assay was as described above. (C) Structure of competitor constructs. pSVpNEO is a backbone vector which has the same SV40 early promoter (21-bp repeats and TATA box) and poly(A) addition signal as pAjoCAT2 (Fig. 2C) but harbors a neomycin resistance gene instead of a cat gene. Into the unique BgIII site, various competitor sequences were inserted. For pWEN NEO or pF441EN NEO constructs, polyomavirus enhancer fragments (nt 4632 through nt 5265) of wild-type or F441, respectively, were inserted. For pW * NEO or pF441 NEO, oligonucleotides of wild-type or F441, respectively, were inserted. A cross in the enhancer fragment or the oligonucleotide indicates the point mutation at nt 5233.
showed that the PvuII-4 fragment (PvuII at nt 5128 through PvuII at nt 5265) containing G at nt 5233 works better both in undifferentiated (PCC3) and differentiated (3T6) cells than the one containing A at that position.
DISCUSSION
The results presented in this communication clearly demonstrated that the F441, but not the wild-type, oligonucleotide sequence can function in a positive way to increase gene expression in F9 cells. The described characteristics of F441 oligonucleotide are consistent with the phenotype of F9 mutants. Also the minimum essential domain to be crucial for F9 mutant enhancer is contained within the oligonucleotide as the segment from nt 5218 to 5239.
It is generally accepted that multiple cellular factors interact with the polyomavirus enhancer to ensure their activity (4, 12, 30, 31) . Now that the F441 oligonucleotide has been shown (this study) to enhance gene expression in F9 cells, the question would be what kind of cellular factors are involved in the activation mechanism. It has been a favored view recently that a point mutation eliminates the binding site for a negatively acting factor which is speculated to be present in F9 cells and to repress the enhancer activity of wild-type sequence (16) . However, it would be difficult to explain with a mere removal of a repressor our results showing that duplication of the F441 oligonucleotide resulted in much higher CAT activity and that the F441 oligonucleotide could compete more efficiently with the F441 enhancer (Fig. 2C) fragment than could the wild-type oligonucleotide. In addition, when the F441 oligonucleotide was used as a dimer in in vivo competition experiments, it inhibited better than the respective monomer (unpublished data). Thus, it would be simplest to infer that the mutation created a binding site or increased the affinity for a positive regulatory factor(s). Indeed, we examined in our recent report (22) the binding of this putative cellular factor to the wild-type and F441 oligonucleotides used in this study. By mobility shift assay and footprinting techniques, a cellular factor(s) present in F9 cells was found to recognize the F441 but not the wild-type oligonucleotide. These results and results presented in this communication together favor the notion that the mutation creates a binding site for, or strengthens the affinity to, a positively functioning factor(s). In relation to this notion, we note that the mutation at nt 5233 from A to G creates a new sequence, (5232)T-Q-G-A-A-T-G(5238), which looks similar to the consensus sequence of the SV40 enhancer core, G-T-G-G-A/T-ArT-A/T-G (44 we found that the wild-type oligonucleotide had only very low, if any, enhancing activity, it may not be surprising that they did not find any biological activities in this region represented by our oligonucleotides. Polyomavirus enhancer is required for viral DNA replication (43) . It has been shown that this enhancer is responsible for tissue-specific DNA replication in F9 (13) , Friend leukemia (9), and neuroblastoma (27) cells. Thus, it would be interesting to see whether the F441 oligonucleotide is more effective than the wild-type oligonucleotide when tested in DNA replication assay. These studies, in combination with the present one, may eventually explain the better growth of F441 mutant virus than of wild-type virus in F9 cells.
Bohnlein and others (3) performed a functional analysis of the region near the F441 (F9-1) mutation. They showed that removal of 40 bp (from nt 5225 through nt 5265) at the 3' end of the F441 (F9-1) PvuII-4 fragment resulted in a drastic drop of enhancing activity when measured in Ltk-or NIH 3T3 cells. In this deleted 40-bp sequence the site of point mutation (nt 5233) was contained. On the basis of this observation, they claimed that the 3' boundary of enhancing activity of F441 (F9-1) PvuII-4 fragment is between nt 5225 and nt 5265. Another interesting observation made by Bohnlein and others (3) was that murine sarcoma virus enhancer fragment was able to activate gene expression in Ltk-and F9 cells only when it was linked to the segment from nt 5207 to 163 of F441 (F9-1), but not when linked to the segment from nt 5241 to 163. The latter segment lacked the site of F441 point mutation. Since the segment of F441 (F9-1) enhancer between nt 5207 and 5265 functioned both as a part of the enhancer and a part of the promoter, they named this 60-bp segment the upstream promoter element (3) . Now, in light of the findings presented in this paper and our recent report (22) , it is most likely that the decrease of enhancer-promoter activity observed by employing various deletions is due to the removal of a factor-binding site which functions in a positive way to increase gene expression. It must also be mentioned that Bohnlein and others (3) did not test the corresponding wild-type sequence in most of their experiments. Thus, it is not clear from their studies whether the segment of wild-type sequence has any enhancer or promoter activity. Since we demonstrated that the wild-type oligonucleotide had only a very low ability to enhance gene expression compared with the F441 oligonucleotide, the term "upstream promoter element" that they proposed is applicable only in the case of the F441 mutation at the present.
The plasmid pA10CAT2 (23) that we used in the present studies does not contain a majority of the SV40 enhancer sequence but retains a remnant of the 72-bp enhancer element that is the P motif defined by Zenke et al. (47) . Thus, it is possible that the oligonucleotide used contained an enhancer-promoter subelement which in combination with this P motif formed an effective enhancer. This might account for the observation that the oligonucleotides augumented cat gene expression only when placed upstream of the cat gene (Fig. 4) .
The conclusion from the present studies is consistent with the fact that F9 mutants carrying the F441 mutation can grow in F9 cells. However, one point is left unexplained, related to the case of some F9 mutants which have duplications of the oligonucleotide region without the point mutation of F441 (42 (21, 27, 28, 39) . Examination of this hypothesis and an attempt to locate the binding sites for a negative regulator will be the subject of future studies.
